Can you interpret the findings on my chest CT scan?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 30, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Chest CT Interpretation: A Systematic Approach

To properly interpret chest CT findings, you must systematically describe the distribution and patterns of parenchymal abnormalities, including ground-glass opacities, consolidation, reticular opacities, centrilobular nodules, interlobular septal thickening, honeycombing, and traction bronchiectasis, using thin-section (≤2.5 mm) contiguous scans with both transverse and coronal reformatted images 1.

Technical Requirements for Optimal Interpretation

Your CT scan should meet specific technical standards:

  • Section thickness: 2.0-2.5 mm or less with contiguous scanning
  • Contrast: IV contrast agent injection is typically recommended
  • Image planes: Both transverse and coronal reformatted images are essential for thorough analysis 1

If the image quality is inadequate according to expert radiologist assessment, a repeat HRCT examination may be necessary, particularly when clinical and functional findings suggest progressive disease 2.

Systematic Description Framework

When interpreting any chest CT, systematically evaluate and document:

1. Distribution Pattern

  • Bilateral vs. unilateral
  • Upper vs. lower lung predominance
  • Peripheral (subpleural) vs. central (peribronchovascular) distribution
  • Diffuse vs. patchy involvement

2. Specific Parenchymal Features

Ground-glass opacities (GGO): Hazy increased attenuation with preserved bronchial and vascular margins

  • When associated with fibrosis/architectural distortion, assess extent visually to nearest 5% for each lung zone 2

Consolidation: Homogeneous increase in pulmonary parenchymal attenuation obscuring vessels

  • Note if nonsegmental, migratory, or persistent

Reticular opacities: Linear opacities forming a network pattern

  • Distinguish between fine and coarse reticulation
  • Assess for associated architectural distortion

Centrilobular nodules: Small nodules separated from pleural surfaces by a clear zone

  • Poorly defined nodules of ground-glass attenuation suggest specific patterns 3

Interlobular septal thickening: Thickening of the septa between secondary pulmonary lobules

3. Signs of Fibrosis (Critical for Prognosis)

Use the term "fibrosis" ONLY when these features are persistently present 4:

  • Traction bronchiectasis or bronchiolectasis: Irregular bronchial dilatation due to surrounding fibrosis
    • Must be persistent on follow-up; transient bronchial dilatation can occur with acute lung injury 4
  • Honeycombing: Clustered cystic airspaces (3-10 mm) with well-defined shared walls in subpleural regions
    • Rare in most conditions; suggests pre-existing fibrosing lung disease if present 4
  • Architectural distortion with volume loss

Quantify traction bronchiectasis extent visually to the nearest 5% for each lung zone, as this correlates with disease progression and mortality 2.

4. Additional Critical Features

Mosaic attenuation/Air trapping:

  • Evaluate on both inspiratory and expiratory images 3
  • The "three-density sign" (ground-glass, normal, and decreased attenuation areas) is highly specific for certain patterns 3

Emphysema:

  • Report if extent >15% of total lung volume, as this associates with complications and progression 2

Pleural abnormalities: Effusions, thickening, or masses

Mediastinal findings: Lymphadenopathy, masses, or vascular abnormalities

Common CT Patterns and Their Significance

Organizing Pneumonia (OP) Pattern

  • Multifocal patchy alveolar opacities
  • Peribronchovascular and/or peripheral distribution
  • May show reversed halo sign 1

Nonspecific Interstitial Pneumonia (NSIP) Pattern

  • Patchy or diffuse ground-glass opacity
  • Peripheral and lower lung zone predominance
  • Progression shows reticulation, traction bronchiectasis, occasionally honeycombing
  • Bilateral and symmetric distribution 1

Hypersensitivity Pneumonitis (HP) Pattern

  • Poorly defined small centrilobular nodules
  • Bilateral ground-glass opacity
  • Mosaic attenuation (lobular areas of decreased attenuation and vascularity) 1

Diffuse Alveolar Damage (DAD/ARDS) Pattern

  • Extensive bilateral ground-glass opacity and dependent consolidation (exudative phase)
  • Traction bronchiectasis and decreased lung volumes (organizing/fibrotic phases) 1

Critical Pitfalls to Avoid

  1. Do not diagnose traction bronchiectasis unless persistent on follow-up - bronchial dilatation can be transient in acute lung injury 4

  2. Do not use "fibrosis" loosely - reserve this term for cases with definitive features (traction bronchiectasis/bronchiolectasis, honeycombing, or architectural distortion with volume loss) 4

  3. Honeycombing after acute processes is rare - if present, strongly consider pre-existing fibrosing lung disease 4

  4. CT patterns are typically nonspecific - diagnosis requires integration with clinical context, temporal relationships, and exclusion of alternative causes 1

  5. Multiple patterns may coexist - report the dominant pattern when this occurs 1

Integration with Clinical Context

The CT pattern must be interpreted alongside:

  • Patient medical history: Drug exposures, environmental exposures, connective tissue disease, immunosuppression
  • Temporal relationships: Timing of symptom onset relative to potential exposures
  • Clinical data: Symptoms, laboratory findings, pulmonary function tests
  • Previous imaging: Compare with prior studies to assess progression or stability 1

When Follow-up Imaging is Indicated

Follow-up chest CT is useful to:

  • Assess changes in findings over time
  • Evaluate response to treatment
  • Detect disease progression

Timing depends on clinical context (symptom severity, clinical course), but for progressive fibrosis, follow-up within 12 months is advisable; anticipate earlier if clinical/functional decline occurs 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.